Table 1 Multiple clinical parameters of 31 AML patients and Lyn expression status of primary AML blasts
Patient number | Age | Sex | Diagnosis | Karyotype | WBC numbers (/μl) | MPO positivity (%) | Lyn intensity (MFI) |
|---|---|---|---|---|---|---|---|
1 | 45 | M | M4E | inv (16) (p13;q22) | 10,900 | 88 | 75.3 |
2 | 56 | F | M2 | t (8;21) (q22;q22) | 23,700 | 100 | 124.5 |
3 | 53 | F | M2 | t (8;21) (q22;q22), -X | 2800 | 100 | 112.1 |
4 | 35 | M | M2 | t (8;21) (q22;q22), del(11) (p13), +15 | 59,300 | ND | 78.8 |
5 | 59 | M | M2 | 21 trisomy | 78,200 | 100 | 53.9 |
6 | 69 | F | M1 | NK | 264,700 | 100 | 24.2 |
7 | 67 | M | M1 | NK | 168,800 | 100 | 29.1 |
8 | 34 | M | M0 | NK | 1500 | 2 | 76.9 |
9 | 43 | M | M4 | NK | 512,800 | 91 | 103.2 |
10 | 21 | M | M1 | t (X;5) (q28;q31) | 6900 | 90 | 71.9 |
11 | 60 | M | M2 | NK | 800 | 6.5 | 60.3 |
12 | 36 | M | M2 | NK | 5300 | 97 | 109.3 |
13 | 56 | M | M2 | NK | 1200 | 94 | 91.8 |
14 | 40 | F | M2 | NK | 69,100 | 99 | 92.9 |
15 | 34 | M | M1 | NK | 43,400 | 20 | 51.1 |
16 | 59 | M | M4 | NK | 99,200 | 39.5 | 45 |
17 | 69 | F | M2 | NK | 149,000 | 98.5 | 35.8 |
18 | 68 | M | MDS/AML | add (11) (q23) | 78,700 | 23.5 | 50.2 |
19 | 55 | M | M2 | NK | 49,400 | 90 | 38.8 |
20 | 51 | F | M5a | t (9;11) (p22;q23), +8 | 1500 | 0 | 71 |
21 | 65 | M | M4 | NK | 96,400 | ND | 27.4 |
22 | 56 | M | M1 | NK | 25,300 | 17.2 | 19.1 |
23 | 61 | M | M2 | Complex | 140,300 | 92 | 92.8 |
24 | 46 | M | M2 | Complex | 60,600 | 31 | 40.2 |
25 | 56 | M | MDS/AML | Complex | 23,000 | ND | 73.8 |
26 | 43 | F | M1 | Complex | 50,600 | 100 | 63 |
27 | 81 | F | M0 | t (9;22) (q34;q11), add(7) (p13), −22 | 95,300 | 1 | 21.1 |
28 | 52 | M | M0 | Complex | 22,300 | 1.5 | 47.2 |
29 | 64 | M | MDS/AML | Complex | 93,200 | 9.5 | 57.6 |
30 | 16 | M | M1 | ND | 403,300 | 93.5 | 79.7 |
31 | 61 | M | M1 | ND | 23,100 | 9 | 70.6 |